Vernuccio Federica, Messina Carlo, Merz Valeria, Cannella Roberto, Midiri Massimo
Radiology Unit, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.
Oncology Unit, A.R.N.A.S. Civico, 90127 Palermo, Italy.
Diagnostics (Basel). 2021 Nov 22;11(11):2166. doi: 10.3390/diagnostics11112166.
The incidence and mortality of pancreatic ductal adenocarcinoma are growing over time. The management of patients with pancreatic ductal adenocarcinoma involves a multidisciplinary team, ideally involving experts from surgery, diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, pathology, geriatric medicine, and palliative care. An adequate staging of pancreatic ductal adenocarcinoma and re-assessment of the tumor after neoadjuvant therapy allows the multidisciplinary team to choose the most appropriate treatment for the patient. This review article discusses advancement in the molecular basis of pancreatic ductal adenocarcinoma, diagnostic tools available for staging and tumor response assessment, and management of resectable or borderline resectable pancreatic cancer.
随着时间的推移,胰腺导管腺癌的发病率和死亡率不断上升。胰腺导管腺癌患者的管理需要多学科团队参与,理想情况下包括外科、诊断成像、介入内镜、医学肿瘤学、放射肿瘤学、病理学、老年医学和姑息治疗等领域的专家。对胰腺导管腺癌进行充分分期以及在新辅助治疗后重新评估肿瘤,有助于多学科团队为患者选择最合适的治疗方案。这篇综述文章讨论了胰腺导管腺癌的分子基础进展、用于分期和肿瘤反应评估的诊断工具,以及可切除或临界可切除胰腺癌的管理。